Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (Nasdaq: IMNM) has appointed Roee Shahar as Executive Vice President, Commercial. Shahar brings over 20 years of experience in launching and commercializing oncology and hematology products from his roles at Seagen, Pfizer, and Eli Lilly & Company. This appointment strengthens Immunome's team in developing targeted oncology therapies.
CEO Clay Siegall highlighted Shahar's expertise in advancing the company's portfolio, particularly AL102, a gamma secretase inhibitor in Phase 3 trials for desmoid tumors. Shahar expressed his commitment to addressing the challenges posed by desmoid tumors, which can cause debilitating pain, deformity, and life-threatening organ damage.
Prior to joining Immunome, Shahar held leadership positions at Pfizer and Seagen, managing hematology portfolios and overseeing commercial activities for products like Adcetris® and Tivdak®. He also served as Marketing Director at Eli Lilly, leading the company's largest oncology brand, Alimta®.
Immunome (Nasdaq: IMNM), a biotechnology company focused on developing targeted cancer therapies, announced the granting of inducement awards to 25 new employees on October 3, 2024. The Compensation Committee approved nonstatutory stock options to purchase 851,400 shares of common stock under the Company's 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $13.43 per share, equal to the Company's closing sales price on October 3, 2024. However, options to purchase 250,000 shares will have an exercise price equal to the closing sales price on the date the grantee's employment begins. The options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over 36 months, subject to continued employment.
Immunome, Inc. (Nasdaq: IMNM) has announced that it will present updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress in Barcelona, September 13-17, 2024. The presentation will be in poster format, titled 'Updated Results of the RINGSIDE Phase 2 Trial and Open-Label Extension of AL102 for the Treatment of Desmoid Tumors' (Abstract #1766P), presented by Dr. Bernd Kasper on September 14, 2024.
Notably, enrollment in the Phase 3 portion of RINGSIDE was completed in February 2024, with topline data expected in the second half of 2025. The poster will be available on Immunome's website after the presentation.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Clay Siegall, PhD, will engage in a fireside chat on Wednesday, September 4, 2024, at 5:35 P.M. Eastern Time.
Interested parties can access the live audio webcast of this presentation through the Investor Relations section of Immunome's website at www.immunome.com. Following the live presentation, a replay of the webcast will be available for approximately 30 days.
Immunome (Nasdaq: IMNM) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Pipeline Progress: Full enrollment completed for Phase 3 RINGSIDE Part B study of AL102 for desmoid tumors, with topline data expected in H2 2025. INDs for IM-1021 and IM-3050 anticipated in Q1 2025.
- Financial Position: Cash, cash equivalents, and marketable securities totaled $278.4 million as of June 30, 2024, with runway expected into 2026.
- Q2 2024 Results: R&D expenses were $29.1 million, in-process R&D expenses were $6.3 million, and G&A expenses were $7.0 million. Net loss reported at $36.1 million.
The company is focusing on developing a broad pipeline of oncology therapies, including ADCs and small molecules, supported by business development efforts and focused research.
Immunome (Nasdaq: IMNM) has announced recent business development activities aimed at expanding its antibody-drug conjugate (ADC) capabilities. The company has acquired exclusive rights to antibody panels from Nectin Therapeutics, Bluefin Biomedicine, and OncoResponse, targeting undisclosed solid tumor targets. This follows earlier acquisitions from Atreca and Zentalis, including the IM-1021 ADC platform technology.
CEO Clay Siegall emphasized Immunome's vision of developing a broad pipeline of targeted therapies, particularly ADCs against novel targets. CSO Jack Higgins highlighted the importance of matching appropriate antibodies, linkers, and payloads to each target's unique biology. The company believes these acquisitions will complement its internal discovery efforts and advance its product pipeline, potentially bringing significant benefits to cancer patients.
Nectin Therapeutics has entered into a global, exclusive license agreement with Immunome Inc. (Nasdaq: IMNM) for antibodies targeting an undisclosed target. The deal allows Immunome exclusive rights to a panel of antibodies, with Nectin receiving an upfront payment and eligibility for milestones and royalties. This agreement enables Nectin to focus on its first-in-class anti-PVR program (NTX1088) and advance novel antibody drug conjugates (ADCs) into clinical development.
Immunome will be responsible for the research, development, manufacturing, and commercialization of products incorporating these antibodies. The company believes that the next generation of transformative ADCs will address novel targets by pairing high-quality antibodies with innovative linker-payload technology.
Immunome has appointed Phil Tsai, PhD, as Chief Technical Officer. Tsai brings nearly 30 years of experience in product development and process optimization, notably in antibody-drug conjugates (ADCs). This strategic move comes as Immunome's pipeline progresses, including a fully enrolled Phase 3 trial of AL102 for desmoid tumors, two IND filings planned for Q1 2025, and additional ADCs in preclinical stages. Tsai's previous roles at Seagen and Pfizer underscore his proficiency in biologics and drug manufacturing. His leadership is expected to fortify Immunome's mission to develop cutting-edge cancer therapies.
Immunome (Nasdaq: IMNM) has completed the acquisition of antibodies and related assets from Atreca for $5.5 million upfront and up to $7 million in clinical development milestones. The purchase includes rights to 28 antibodies and various materials, enhancing Immunome's ADC (antibody-drug conjugates) portfolio. Immunome's Chief Scientific Officer, Jack Higgins, emphasizes that the newly acquired antibodies align with their strategy targeting novel and unexplored cancer therapy targets. CEO Clay Siegall mentioned that this acquisition aims to expand Immunome's ADC portfolio cost-effectively and accelerate the development of innovative cancer treatments.
Immunome (Nasdaq: IMNM) has announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Rosett, previously Executive Vice President of Operations and Interim CFO since January 2024, has played a key role in Immunome's recent strategic moves including the merger with Morphimmune and financial transactions worth over $350 million. CEO Clay Siegall emphasized Rosett's strategic insight and financial expertise as vital for advancing the company's pipeline, including the Phase 3 RINGSIDE trial of AL102 and preparing IM-1021 and IM-3050 for IND submission. Rosett's background includes senior roles at Morphimmune and experience at Research Bridge Partners, Google, and Boston Consulting Group.